4 GLP-1 medicines and kidney disease: what you need to know
N Engl J Med 344(18):13431350 Pan XR, Li GW, Hu YH et al (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance
Purity percentage is not an identity confirmation
However, updated standards indicate that other medications, including GLP-1 RAs, may be used as first-line therapy in patients at high risk for atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease
Multiple sclerosis, an autoimmune demyelinating disease of the central nervous system, may benefit from the anti-inflammatory and neuroprotective properties of GLP-1RAs
For patients discontinuing tirzepatide, blood glucose levels should be monitored closely as the medication's glucose-lowering effects diminish